title: Hepatotoxicity in the treatment of tuberculosis using moxifloxacin-containing regimens.
authors.forename: Catherine H
authors.initials: CH
authors.lastname: Roberts
authors.forename: Colette
authors.initials: C
authors.lastname: Smith
authors.forename: Ronan
authors.initials: R
authors.lastname: Breen
authors.forename: Radha
authors.initials: R
authors.lastname: Gadhok
authors.forename: Michael
authors.initials: M
authors.lastname: Murphy
authors.forename: Anna
authors.initials: A
authors.lastname: Aryee
authors.forename: Ian
authors.initials: I
authors.lastname: Cropley
authors.forename: Sanjay
authors.initials: S
authors.lastname: Bhagani
authors.forename: Susan
authors.initials: S
authors.lastname: Hopkins
authors.forename: Marc
authors.initials: M
authors.lastname: Lipman
mesh_terms: D000995:Antitubercular Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D001372:Aza Compounds / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D015331:Cohort Studies; D004359:Drug Therapy, Combination; D024841:Fluoroquinolones; D006801:Humans; D016015:Logistic Models; D000077266:Moxifloxacin; D015999:Multivariate Analysis; D011804:Quinolines / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D012189:Retrospective Studies; D014376:Tuberculosis / Q000188:drug therapy*
chemical_list: D000995:Antitubercular Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D000077266:Moxifloxacin